Why the study?
Do platelet glycoprotein IIb/IIIa inhibitors reduce ischemic events in patients undergoing percutaneous coronary interventions?
Do platelet glycoprotein IIb/IIIa inhibitors reduce ischemic events in patients undergoing percutaneous coronary interventions?
This review highlights that GP IIb/IIIa inhibitors reduce ischemic events, short-term death, and non-fatal MI in patients undergoing PCI, including those with diabetes.
No takes yet. Share an insight, caveat, or question.
Supports GP IIb/IIIa inhibitor use in PCI to reduce ischemic events; leaves open optimal selection in contemporary practice.
Anne et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: